Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
As of today, Vertex Pharmaceuticals(VRTX) shares are valued at $444.90. The company's market cap stands at 112.92B, with a P/E ratio of 25.83.
As of 2026-06-11, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $435.21 and $445.19. The current price stands at $444.90, placing the stock +2.2% above today's low and -0.1% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 576.35K, compared to an average daily volume of 1.31M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $507.92 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $507.92 at its peak.
VRTX News
The data were consistent with results previously observed in adolescent and adult patients. Phase 3 Studies Show High Rates Of Clinical Response An interim an...
Vertex Pharmaceuticals (VRTX) announced data demonstrating the clinical benefits of Casgevy in people ages 5 years and older living with severe sickle cell dise...
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported new clinical data for its next-generation cystic fibrosis therapy ALYFTREK in young children. The company also...
Analyst ratings
81%
of 36 ratingsMore VRTX News
Vertex Pharmaceuticals (VRTX) announced data demonstrating the potentially transformative impact of treating cystic fibrosis with ALYFTREK in children ages 2 to...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.